Eledon Pharmaceuticals (ELDN) just shared results from its Phase 2 BESTOW trial on tegoprubart for kidney transplant rejection. While the main goal was not fully met, the data points to meaningful preservation of kidney function.
See our latest analysis for Eledon Pharmaceuticals.
Shares of Eledon Pharmaceuticals have taken a steep dive recently, with the share price dropping over 49% in a single day and more than 52% over the past week following news from the Phase 2 trial. This latest setback has added to what has been a tough 12 months for long-term holders, reflected in a 57% decline in total shareholder return, though the company’s advancement toward Phase 3 keeps the door open for a potential turnaround if clinical results improve and market sentiment shifts.
If the ups and downs of biotech spark your curiosity, now is a good time to see what else is happening across the industry. See the full list for free.
With the share price in freefall but analyst targets suggesting substantial upside, it is worth asking: are investors overlooking possible long-term value here, or is the market already factoring in all that future growth?
Compared to its peers and the broader market, Eledon Pharmaceuticals is trading at a price-to-earnings ratio of 8.4x. This compares to the US market average of 18.1x and the US Biotechs industry average of 17x, making the current price appear undervalued by these benchmarks.
The price-to-earnings (P/E) ratio indicates how much investors are willing to pay per dollar of earnings. In the biotech sector, this figure provides a snapshot of market confidence in a company’s ability to generate profits, especially after achieving profitability.
Eledon’s P/E ratio is significantly below both the industry and peer averages. This suggests that either the market is not fully pricing in its profitability or has concerns about its growth prospects. Both the peer group average (16.9x) and the estimated fair P/E (10.7x) are materially higher, highlighting that the stock could see upward multiple expansion if sentiment shifts or fundamentals improve.
Explore the SWS fair ratio for Eledon Pharmaceuticals
Result: Price-to-Earnings of 8.4x (UNDERVALUED)
However, further setbacks in clinical trials or continued weak financial results could easily undermine any momentum and keep investor confidence subdued.
Find out about the key risks to this Eledon Pharmaceuticals narrative.
If you would rather dive into the numbers and form your own perspective, it takes less than three minutes to develop your personal view. Do it your way.
